Drug Safety (2019) 42:1045‚Äì1053
https://doi.org/10.1007/s40264-019-00831-4

ORIGINAL RESEARCH ARTICLE

Enabling Data‚ÄëDriven Clinical Quality Assurance: Predicting Adverse
Event Reporting in Clinical Trials Using Machine Learning
Timoth√© M√©nard1

¬∑ Yves Barmaz1 ¬∑ Bj√∂rn Koneswarakantha1 ¬∑ Rich Bowling2 ¬∑ Leszek Popko1

Published online: 23 May 2019
¬© The Author(s) 2019

Abstract
Introduction Adverse event (AE) under-reporting has been a recurrent issue raised during health authorities Good Clinical
Practices (GCP) inspections and audits. Moreover, safety under-reporting poses a risk to patient safety and data integrity.
The current clinical Quality Assurance (QA) practices used to detect AE under-reporting rely heavily on investigator site
and study audits. Yet several sponsors and institutions have had repeated findings related to safety reporting, and this has led
to delays in regulatory submissions. Recent developments in data management and IT systems allow data scientists to apply
techniques such as machine learning to detect AE under-reporting in an automated fashion.
Objective In this project, we developed a predictive model that enables Roche/Genentech Quality Program Leads oversight
of AE reporting at the program, study, site, and patient level. This project was part of a broader effort at Roche/Genentech
Product Development Quality to apply advanced analytics to augment and complement traditional clinical QA approaches.
Method We used a curated data set from 104 completed Roche/Genentech sponsored clinical studies to train a machine
learning model to predict the expected number of AEs. Our final model used 54 features built on patient (e.g., demographics,
vitals) and study attributes (e.g., molecule class, disease area).
Results In order to evaluate model performance, we tested how well it would detect simulated test cases based on data
not used for model training. For relevant simulation scenarios of 25%, 50%, and 75% under-reporting on the site level, our
model scored an area under the curve (AUC) of the receiver operating characteristic (ROC) curve of 0.62, 0.79, and 0.92,
respectively.
Conclusion The model has been deployed to evaluate safety reporting performance in a set of ongoing studies in the form
of a QA/dashboard cockpit available to Roche Quality Program Leads. Applicability and production performance will be
assessed over the next 12‚Äì24 months in which we will develop a validation strategy to fully integrate our model into Roche
QA processes.

1 Introduction
Compliance with the fundamental principles of Good Clinical Practice (GCP) ensures the rights, safety, and wellbeing of research subjects and ensures the integrity of clinical
research data. Trial sponsors are required by the International Conference on Harmonization (ICH) guidelines to
Electronic supplementary material The online version of this
article (https‚Äã://doi.org/10.1007/s4026‚Äã4-019-00831‚Äã-4) contains
supplementary material, which is available to authorized users.
* Timoth√© M√©nard
timothemenard@gmail.com
1

F. Hoffmann-La Roche, Basel, Switzerland

2

Genentech - A Member of the Roche group,
South San Francisco, USA

implement and maintain quality assurance (QA) and quality
control systems to achieve these objectives [1].
One of the main issues reported in GCP health authority
inspections and sponsor audits is the lack of adverse event
(AE) reporting from the investigator sites to the sponsor [2,

Key Points
Safety under-reporting is a recurrent issue in clinical
trials.
We built a machine learning model that detects underreporting of adverse events.
This model is used to trigger quality assurance activities
to protect patient safety and to avoid delayed filing.
Vol.:(0123456789)

1046

3]. Under-reporting poses a significant risk to data integrity
and to patient safety [1, 4‚Äì6]. Furthermore, several sponsors
have failed to mitigate AE under-reporting and this has led
to delays in regulatory submission or to non-approval of
new drugs [6, 7].
Finally, there are also some concerns that safety data collected in randomized controlled trials (RCTs) have limitations [8] that could be aggravated by AE under-reporting.
First of all, the sample size of RCTs is tailored to detect drug
efficacy but not to statistically detect incidents that occur
with a lower rate than a positive drug response. Furthermore,
RCT AE reporting and analysis standards (lack of time-toevent reporting, using standardized incidence ratios, and
normalizing by patient-years) favor the detection of AEs that
can occur with a uniform risk rate over the entire observation
window over detection of those AEs that have high risk rates
at a specific time frame inside the observation window [8].
In the light of these limitations, which make statistical AE
detection in the setting of RCTs very challenging, it becomes
evident that AE under-reporting poses a great risk to the
detection of AEs and to patient safety.
Current clinical QA practices heavily rely on audits to
detect sites or studies with quality issues, including AE
under-reporting [9]. The increasing number of clinical trials and sites and the growing complexity of study designs
make it challenging to detect AE under-reporting. Current
site monitoring strategies, which rely on on-site source
data verification (SDV) and on risk-based approaches, are
attempting to address the issue [10, 11], yet AE underreporting remains as a common audit and inspection finding [2].
A holistic QA approach that addresses the above raised
issues concerning AE reporting is not currently available.
However, the industry has recently been trying to leverage
modern developments in data management and IT systems
that facilitate the cross-analysis of clinical studies. Statistical analysis can be performed on this data based on
certain attributes to help identify issues in safety reporting
and to be able to estimate or predict the number of AEs
reported per patient. We used our combined, historical
clinical study data to develop a predictive model for the
expected number of AEs per patient based on study and
patient attributes including but not limited to therapeutic area, study design, mechanism of drug action, mode
of administration, vitals, commonly assessed laboratory
measurements, medical history and concomitant medications. We propose a model that will provide insight to
clinical QA professionals to detect and mitigate safety
reporting risks more holistically and efficiently.
The development of a predictive model that can help
detect under-reporting requires a deep understanding of
data science, clinical safety, and QA. The project has been
conducted by the Roche/Genentech quality data analytics

T. M√©nard et al.

team, a team of data scientists, in collaboration with
Roche/Genentech clinical and QA subject matter experts
(SMEs).
The mission of the Roche/Genentech quality data analytics team is to build data-driven solutions for clinical
QA at Roche/Genentech to complement and augment traditional QA approaches to improve the quality and oversight of GCP‚Äîand Good Pharmacovigilance Practices
(GVP)‚Äîregulated activities.

2‚ÄÇMethod
2.1‚ÄÇOutline and Assumptions
The objective of this proof-of-concept (PoC) effort was to
develop and assess the performance of a predictive model
that can help detect AE under-reporting and to develop a
visual interface for QA professionals. The scope of this
PoC was to predict AE under-reporting, not predicting
adverse drug reactions that should occur in clinical trials.
GCPs require all AEs, whether or not there might be a
causal relationship between the intake of the drug and the
events, to be reported timely to the sponsor [1].
The identification of study investigator sites suspected
of under-reporting amounts to an unsupervised anomaly
detection problem [12]. In this class of problems, one tries
to identify which elements of a data set are anomalous;
for example, which objects in a production line show a
defect, or which study sites are not compliant with GCP.
The main difference from a classification task is that the
data points are unlabeled. Under the assumption that a
majority of them behave normally, a possible approach to
solve these problems is to fit a probability distribution to
the data and flag as anomalous those data points that have
a likelihood below a certain threshold. The performance
of the anomaly detector can then be assessed with a small
sample of anomalous points, either manually detected or
simulated, and regular ones in the same way as one would
assess a classifier, namely with metrics such as the area
under the receiver operating characteristic (ROC) curve,
precision, recall, or accuracy.
Working on the assumption that the curated data set of
finished and completed studies used for model training
contained a majority of compliant study sites (see also
Sect. 2.2.1.), we could build a probabilistic model for
the random variable Ysite describing the number of AEs
reported by a given study site. We collected data from each
site, which were modeled as a random variable Xsite , a feature vector that we believed had a direct influence on Ysite.
When we considered a new study site and made observations of the feature vector xsite and of the number ysite
of reported AEs, from the conditional probability density

1047

Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning

(
)
p Ysite |Xsite of our model we computed the probability of
observing this number of AEs or less, that we defined as
the significance level. We then picked a threshold and we
decided to act for significance levels below it.
Clinical trial data can be interpreted as a set of multivariate time series of measurements for each patient in
the study (some of them being constant, for instance the
demographic data). Furthermore, this data is typically collected during the patient visits, which is when AEs are
reported to the investigator [13]. Therefore, we decomposed the number of AEs ysite reported by a site into the
sum of the numbers of AEs reported by the corresponding
patients,
‚àë
Ysite =
Ypatient ,

(
)
Ysite ‚àº Poi ùúÉsite ,

sùúÉsite =

‚àë

ùúÉpatient .

patient ‚àà site

Furthermore, assuming our estimate of ùúÉsite was accurate,
we could calculate the significance level of an observation
of ysite adverse events,
y

k
site
ùúÉsite
(
)
(
) ‚àë
S xsite , ysite = P Ysite ‚â§ ysite |xsite =
e‚àíùúÉsite .
k!
k=0

did not hold perfectly and
( Even if these assumptions
)
P Ysite ‚â§ ysite |xsite was thus not a well-calibrated probability, we could still use it as a scoring function to detect
under-reporting and evaluate its discriminating power with
a ROC curve.

patient ‚àà site

and similarly, the number of AEs reported by a patient into
the sum of the numbers of AEs reported at each visit,
‚àë
Ypatient =
Yvisit .
visit ‚àà patient

We could make predictions either at the site level, patient
level, or visit level. Given the granularity of clinical data, we
decided to focus on the visit level. A sudden change in vital
parameters such as the weight could be indicative of health
deterioration and thus the occurrence of AEs [14]. Moreover,
once we used this model on ongoing studies, we wanted to be
able to update our predictions as new data from the sites came
in, which was easier to do if we started at the visit level.
( We were )thus interested in the probability density
p Yvisit |Xvisit conditioned on the feature vector Xvisit that summarizes information on the patient known at the time of the
visit. To estimate the relation between Xvisit and Yvisit , given
the amount of historical data at our disposal, we decided to
apply machine learning algorithms. The usual least squared
error regression was ill-advised in this situation as it would
imply that predicting zero AE instead of five costs the same
as predicting 95 instead of 100, which was not the case. We
could have considered logarithmic least squares, but since we
were dealing with a count variable, it was best to minimize the
Poisson deviance. In this class of models, the random variable
Yvisit was interpreted as a Poisson process,
)
(
Yvisit ‚àº Poi ùúÉvisit ,
where we had to express the Poisson parameter ùúÉvisit as a
function of Xvisit . Due to the complexity of the underlying biology of AEs, the empirical approach seemed more
promising than theoretical modeling and we decided to
use machine learning for this task. The advantage of this
approach was that Poisson processes are additive in their
parameters, so we immediately obtained:
‚àë
(
)
Ypatient ‚àº Poi ùúÉpatient , ùúÉpatient =
ùúÉvisit ,
visit ‚àà patient

2.2‚ÄÇData
2.2.1‚ÄÇRaw Data
The raw data set we used came from Roche/Genentech-sponsored clinical trials. We used common data attributes from
104 completed studies that covered various molecule types
and disease areas. The data set included 3231 individual
investigator sites, with 18,682 study subjects that underwent
288,254 study visits. Of note, any study subject data was
used in a de-identified format. To mitigate the risk of having
studies with under-reporting in our data set, we used only
data from completed and terminated clinical trials, where
AE reconciliation and SDV had been performed as part of
the study closure activities. The six common patient data
attributes across the studies that we selected in our curated
data set were demographics, medical history, concomitant
medications, vitals, visits, and adverse events, following the
Study Data Tabulation Model (SDTM) standard [15]. As
mentioned above, we focused on the visits, which we labeled
by study code, patient number, and visit date. We also considered study attributes available in the Roche Clinical Trial
Management System (CTMS) and included them in our data
set: study type, route of administration, concomitant agents,
disease area, blinding, randomization, and study phase. We
used a different classification for the molecule classes and
the disease areas from the one used in the Roche CTMS
to ensure their clinical relevance in terms of AE reporting.
Molecules were classified using the Anatomical Therapeutic
Chemical (ATC) classification system [16]. For the disease
areas, we used a simple classification that reflects the populations enrolled in our clinical trials (healthy participants,
malignancies, autoimmune diseases, neurodegenerative
diseases, respiratory diseases, skin disorders, lung diseases,
infectious diseases, others). As we needed to have a model
that can generalize to the diversity and volume of clinical
studies we run at Roche/Genentech, we purposely chose

1048

T. M√©nard et al.

study and patient attributes that are systematically captured
in our clinical programs. See Table 1 below for an overview
of our curated data set.
2.2.2‚ÄÇFeatures and Targets
Each AE was assigned to the first visit following the onset
date and all AEs assigned to a specific visit were aggregated
into the observation yvisit , that we tried to predict.
To construct features, we needed to project all data
attributes to the visit level. For demographic characteristics that were constant, such as sex and ethnicity, or had
a direct dependence on the date, such as age, this was
straightforward. For medical history, we counted the
events that occurred before every visit. Since new entries
from screening in the medical history section of the electronic case report form (eCRF) normally correspond to
AEs that should get reported, they provide a strong signal.
Similarly, we counted concomitant medications, because
the more drugs a patient receives, the more AEs he will
likely experience [14, 17]. From the vitals reported at each
visit, we included blood pressure and its relative variation
since the previous visit. We also used patient weight, its
relative variation since the previous visit, and the trend
over the last 3 weeks as attributes, as a change in weight
could be linked to a worsening of health and hence the
occurrence of AEs. The disease area, the molecule class
and mechanism of action, and the route of administration
were also included as categorical features, as these characteristics have a strong influence on the type and number of
AEs [14]. We picked the drug class instead of the molecule
itself as a feature to ensure generalization to previously
unseen drugs, consenting to increase the bias in order to
reduce the variance. For a selection of the created features
and how they correlate with the number of reported AEs,
see Electronic Supplementary Material 1.
Before regrouping the features in the vector xvisit , we
used one-hot encoding on the categorical variables, we

raised the age variable to the power 1.4 in order to have
a roughly normal distribution, and we standardized the
continuous variables.
Once the set of features was selected, we relied on
machine learning algorithms to pick the best ones through
optimization of a loss function.
In our model, we used 54 features, with the highest
contribution coming from the following ones:
‚Ä¢ Number of previous visits made by the patient
‚Ä¢ Cumulative count of concomitant medications up to the

current visit

‚Ä¢ Disease is a malignancy (Boolean)
‚Ä¢ Disease is pulmonary but non-malignant (Boolean)
‚Ä¢ Administration is oral (Boolean)

See Electronic Supplementary Material 2 for the full
list of features used in the final model.
2.2.3‚ÄÇTraining, Validation, and Test Sets
As in most machine learning projects, we split our data
into a training, a validation, and a test set. The training set
was used to minimize the loss function with respect to the
parameters of the model, the validation set to control for
overfitting and to pick the hyper-parameters of the model
via grid search, and the test set finally to assess the generalization performance to new data [18]. In our case, the
test set was also used for the simulation of under-reporting
introduced in the outline.
It should
( be noted) that we could not randomly assign
each pair xvisit , yvisit to one of the three sets as we were
ultimately interested in ysite , the count of adverse events
reported by a single site. We needed to work on subsets
{(
)
}
Vsite = xvisit , yvisit |visit ‚àà site and assign each of them
to one of the training, validation, and test sets. At the level

Table 1‚ÄÇ‚ÄâAttributes available in our curated data-set
Level

Source

Extracted data

Patient
Visit
Visit
Visit
Visit
Visit
Study

SDTM demographics
SDTM medical history
SDTM concomitant medications
SDTM vitals
SDTM visits
SDTM adverse events
Clinical Trial Management System

Age, sex, ethnicity
Number of co-occurring conditions
Number of concomitant medications
Height, weight, blood pressure
Number of previous visits
Number of reported AEs
Intervention type, route of administration, use of concomitant
agents, phase, randomization, blinding, molecule class, disease
type

AEs adverse events, SDTM study data tabulation model

1049

Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning

of the prediction for yvisit , this prevented data leakage due
to a patient finding himself in two different sets.
We assumed that the molecule class had a significant influence on the number of AEs [17]; therefore, we
decided to stratify the sites by this factor when splitting
them into the training, validation, and test sets, to ensure
a representation of every class in each set.
While respecting these constraints, we tried to assign
roughly 60% of the sites to the training set and 20% each
to the validation and test sets.

where QD denotes the quantile function of probability distribution D. Table 2 summarizes a few values of this function.
We kept in the under-reporting sample EUR only the sites
with ysite ‚â• 8.

2.3‚ÄÇUnder‚ÄëReporting Simulation

2.3.2‚ÄÇRatio Scenarios

(
)
In order to evaluate how the significance level S xsite , ysite
discriminates under-reporting anomalies from normal behavior, we had to simulate under-reporting sites due to the lack of
real-world examples where all necessary data attributes had
been captured. To do so, we picked a sample EUR of the test
set Etest where we artificially lowered the AE count ysite to
(simulate) under-reporting. Explicitly, for each pair
xsite , ysite ‚àà EUR from
) of the test set, we built an
( this sample
, with y < ysite . How much
under-reporting pair xsite , y

In the ‚Äòratio scenarios‚Äô, we arbitrarily kept a fixed fraction of
AEs. We tried several values, namely y = 0.75 √ó ysite (25%
site
under-reporting), y = 0.5 √ó ysite (50% under-reporting),
site
y = 0.33 √ó ysite (67% under-reporting), y = 0.25 √ó ysite
site
site
(75% under-reporting) and y = 0.10 √ó ysite (90% undersite
reporting), and again we kept in the under-reporting sample
EUR only the sites with ysite ‚â• 8.

site

site

smaller than ysite depended on how we wanted to define underreporting, which required input from subject matter experts.
We defined three types of scenarios (described below), one
following a statistical approach, one reducing all AEs by a
fixed ratio, and one simulating
absence of reporting.
{(
)
}
The negative cases xsite , ysite , lsite = 0 |site ‚àà Etest of
under-reporting, where lsite denotes the label for the classification problem, from
{( the test set could)then be merged with}the
xsite , y , lsite = 1 |site ‚àà EUR ‚äÇ Etest of
positive cases
site

under-reporting from the simulated under-reporting set to form
the classification test set, from which we could build
)
( a ROC
(
)
curve for the significance levels S xsite , ysite and S xsite , y
.
site

We selected a sample instead of the whole test set to exclude
sites where the difference between ysite and y would be too
site
low to be worrisome from a quality perspective and would
therefore add unnecessary noise in the evaluation of the models. In defining the under-reporting scenarios, we thus had to
specify y as a function of ysite and which sites to keep in EUR .

given by the observed number ysite of AEs, and a low number
of reported AEs(could) be defined as the first percentile of this
distribution Poi ysite ,

y

site

= QPoi(ysite ) (0.01),

2.3.3‚ÄÇZero Scenario
The ‚Äòzero scenario‚Äô simulated the absence of reporting from
the smaller sites, so we set y = 0 and retained only those
site
with 10 patients or fewer but at least six reported AEs in
total for the positive cases. In our test set, those represented
329 sites out of 643.

2.4‚ÄÇMachine Learning Algorithm
The problem of modeling the number of adverse
events reported
(
) on a given visit as a Poisson process,
Yvisit ‚àº Poi ùúÉvisit , could be tackled with machine learning.
Given observations xvisit and yvisit of the features and numbers
( of)reported AEs, the goal was to find an approximation
f xvisit of yvisit that minimizes a loss function,
‚àë (
(
))
L(f ) =
l yvisit , f xvisit ,
visit

site

2.3.1‚ÄÇStatistical Scenario
The ‚Äòstatistical scenario‚Äô relied on the assumption that the total
number of AEs reported
( by )a single site followed a Poisson
distribution, Ysite ‚àº Poi ùúÉsite . Our best estimate for ùúÉsite was

where the sum runs
( over( all visits
)) in the training set and the
individual loss l yvisit , f xvisit penalizes inaccuracy in the
individual prediction of yvisit . Its exact form depends on the
type of modeling. For Poisson processes, it is the Poisson
deviance

Table 2‚ÄÇ‚ÄâExamples of simulated values of under-reporting in the statistical scenario
ysite
y
site

1
0

5
1

10
3

50
34

100
77

500
449

1000
927

1050

T. M√©nard et al.

(
)
(
))
(
(
)
yvisit
l yvisit , f xvisit = 2 yvisit log (
) ‚àí yvisit + f xvisit .
f xvisit
Several algorithms are suitable to optimize this loss function, the most commonly used are generalized linear models
[19], gradient boosting machines [20], and neural networks.
We dismissed neural networks as we felt the limited signal
to noise ratio did not justify the investment in computational
power and architecture design. We tried the other two algorithms and obtained the best performance with gradient
boosting machines, so we settled for this one. A thorough
introduction can be found in The elements of statistical
learning: data mining, inference and prediction [21], but
we provide a brief overview of the algorithm here.
A regression tree would try to solve this optimization
problem by successively splitting regions (of the) feature
space in halves and assigning a value for f xvisit to each
region of the final partition. While the accuracy of a single
tree is fairly low, ensemble methods such as gradient boosting machines or random forests aggregate the predictions
of many trees in a weighted average and achieve a much
better performance. A gradient boosting machine constructs
this average iteratively: it starts with a simple estimate and
successively updates its current prediction with a new tree
that tries to replicate the current gradient of the loss function. This approach was inspired by the gradient descent
methods widely used in optimization, which gave the name
of the algorithm.

Fig. 1‚ÄÇ‚ÄâReceiver operating characteristic (ROC) curve for the statistical scenario

2.5‚ÄÇImplementation
We stored our data in a Hadoop [22] cluster to ensure scalability to an arbitrary number of studies, with the data
preprocessing and feature engineering coded in PySpark.
Several software packages offer more or less sophisticated
implementations of gradient boosting machines. They
mainly differ by the way single trees are fit to the current
gradient of the loss function and by different performance
optimizations. We used the Sparkling Water [23] implementation of H2O, which would allow our entire pipeline to be
easily exported as a Spark application if we decided, for
instance, to move to a cloud-based solution.

Fig. 2‚ÄÇ‚ÄâReceiver operating characteristic (ROC) curve for the zero scenario (for small investigator sites)

3‚ÄÇResults
Based on the simulated under-reporting scenarios described
in Sect. 2.3 and the predictions of our trained gradient boosting machines on the test set, we obtained the following ROC
curves for the task of detecting under-reporting with a score
function given by the significance levels of the observations
and the simulated reduced values. For the statistical scenario

Fig. 3‚ÄÇ‚ÄâReceiver operating characteristic (ROC) curves for the percentage scenarios. UR under-reporting

1051

Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning

(see Sect. 2.3.2), our model scored an area under the ROC
curve of 0.67 (see Fig. 1).
For the zero scenario (small investigator site), our model
scored an area under the ROC curve of 0.97 (see Fig. 2). For
the scenarios of 25%, 50%, 67%, and 75% under-reporting
on the site level, our model scored an area under the ROC
curve of 0.62, 0.79, 0.89, and 0.92, respectively (see Fig. 3).
We used a trade-off between true positive rates and false positive rates to define alert levels in order to prioritize the study
sites to be further investigated. See Sect. 4 for more details.

4‚ÄÇDiscussion
We built a visual and interactive dashboard using
¬≠Tableau¬Æ. Data from ongoing clinical studies were collected on a monthly basis and fed to our model in order
to get updated values and predictions for the volume of
reported AEs. Of note, it is planned to feed our model
with data from ongoing clinical studies on a daily basis to
generate updated predictions in real time.
In order to detect sites that were at risk of under-reporting, we used the findings from the simulation scenarios
to derive an alert level (AL) flagging system. The significance level score for each site allowed us to rank the sites
by risk of under-reporting; however, a reasonable cut-off
had to be found to determine which of the high-risk sites
needed to be flagged for the end user. In order to calculate the best trade-off between maximizing true positive
rate (tpr) and minimizing false positive rate (fpr), we used
Youden‚Äôs J statistics [24] on each simulation scenario. We
identified three consecutive threshold values that allowed
us to group all sites into four groups (AL3, AL2, AL1,
AL0), with AL3 indicating the highest risk and AL0 the
lowest risk for under-reporting. The tpr for all simulation
scenarios and the corresponding fpr are listed in Table 3.
The fpr of each alert level is indicative of the minimum
percentage of sites that will be flagged in a set of data from
ongoing studies, all of which will need to be screened in
order to detect true under-reporting sites with the indicated
performance metrics. If the percentage of under-reporting
sites in our sample were exceptionally high (> 1%), the
Table 3‚ÄÇ‚ÄâPerformance metrics
for sites grouped by different
alert levels

fpr
Zero scenario tpr
75% under-reporting tpr
67% under-reporting tpr
50% under-reporting tpr
25% under-reporting tpr

percentage of sites being flagged would increase accordingly but without affecting the tpr metric. Based on those
assumptions, we can interpret the performance for AL3
as follows: by reviewing the top ~ 14% of the sites with
the highest under-reporting risk predicted by our model,
we will identify 95% of small sites not reporting any
AEs, 80% of all sites with 75% under-reporting, 72% of
all sites with 67% under-reporting, 50% of all sites with
50% under-reporting and 31% of all sites with 25% AE
under-reporting. We can reasonably increase these detection rates by including sites flagged with AL2 and AL1
into our reviewing process.
The alert levels are displayed on the dashboard along
with other important site parameters. Access to it has been
granted to quality program leads at Roche/Genentech.
It allows a holistic and nearly real-time quality oversight
for safety reporting. Studies and sites that are suspected of
under-reporting will be considered at risk and will trigger
additional quality activities (e.g., audits). The tool will also
be used by auditors to select sites and/or patients for review
during study or investigator site audits.
As explained in the introduction, current clinical QA
practices heavily rely on investigator and study audits [9].
For quality oversight activities, our predictive model has a
significant advantage, as it enables holistic and real-time
monitoring of safety reporting at various levels, which had
not been possible when solely relying upon audits. With the
current performance, a site that reported significantly fewer
AEs than predicted (e.g., 67% under-reporting and more,
see Sect. 3) would very likely be detected early enough
that quality program leads can trigger mitigation activities.
For audit selection and planning, risk factors such as high
recruiting sites/studies and other quality indicators were
used to prioritize audits. The output of our predictive model
could be integrated to refine the current risk assessment process. During audits, the current practice for site or patient
selection was mainly based on random sampling and adherence to defined quality indicators; hence our model enables
data-driven selection of patients (during site audits) and of
study sites (during study audits).
Health Authorities inspectors and GCP requirements do
not provide any defined threshold on what is considered AE

Alert level 3

Alert level 2‚Äì3

Alert level 1‚Äì3

Alert level 0

0.14
0.95
0.80
0.72
0.50
0.31

0.22
0.99
0.90
0.84
0.64
0.37

0.25
0.99
0.91
0.86
0.66
0.39

0.75
0.01
0.09
0.14
0.36
0.61

fpr false positive rate, tpr true positive rate

1052

under-reporting. However, the regulatory guidelines emphasize that a risk-based approach should be applied and quality
assurance teams must focus on the highest risk areas [1‚Äì3].
Hence, we proposed various thresholds of under-reporting
(Sect. 2.3.1) to assess if the model performance will enable
detection of the most problematic investigator sites. In this
context, our model allows us to pursue a risk-based approach
when screening sites for safety reporting issues. By focusing
on 14% of the high-risk study sites as ranked by our model,
we will be able to detect 95% of small sites with no underreporting, 80% of sites with 75% under-reporting, 72%
of sites with 67% under-reporting, 50% of sites with 50%
under-reporting, and 31% of sites with 25% under-reporting. The level of performance of our predictive model was
perfectly acceptable in the context of being used by quality
program leads (program, study, and site oversight), quality
strategists (audit selection and planning) and auditors (site
and patient review selection), as it provided a more robust
quantification of the risk of under-reporting than the current
standard. Our predictive model and its associated visualization have been designed to be fit for purpose for clinical
QA. However, we will share our approach, our models, and
the associated tool with other teams responsible for study
oversights, namely study teams and clinical monitors. Such
a tool and approach could also be used for site monitoring,
especially in the context of centralized and/or risk-based
monitoring.

4.1‚ÄÇLimitations
The main obstacle we had to overcome in this work was
the absence of labeled positive cases of under-reporting to
evaluate our models. As a work-around, we simulated underreporting at the site level because our end-goal was the identification of suspicious sites, and summation across several
patients made our somehow simplistic statistical scenarios
more likely than if we had applied them at patient level. We
picked our approach of combining machine learning with a
probabilistic interpretation of the results for computational
reasons and the immediate availability of off-the-shelf products. The price to pay was that the significance levels we
computed were not well-calibrated probabilities, because
they failed to capture the uncertainty in the prediction of
ùúÉvisit and by extension of ùúÉpatient . As a result, we could not be
certain that a good performance at detecting under-reporting
at the site level would translate well to the patient level.
A fully probabilistic, well-calibrated model would be more
reliable. Potential approaches include probabilistic graphical
models and Bayesian neural networks.
Our models have been trained solely on Roche/Genentech-sponsored clinical trial data. Access to clinical trial
data from other sponsors would be a prerequisite to assess
the performance of our models on non-Roche/Genentech

T. M√©nard et al.

clinical studies. We are considering approaching other sponsors and regulators to further assess the performance of our
models and possibly teaming up to build the next version
of the model to detect AE under-reporting. Further analysis
using real-world data will also be performed with an upcoming collaboration effort with Flatiron Health that provide
curated real-world data. Once we have extended our data
corpus, we will seek to develop a new modeling strategy
that allows us to differentiate between study types during
the evaluation of model performance.
At the time of the experiment, we did not have access to
a curated data set that would allow us to map clinical investigator sites to specific countries/regions. As AE reporting
culture might differ from one country/region to another [25],
we are considering the integration of geographical locations
of studies and sites as a feature in the next version of our
model.

5‚ÄÇConclusions
In this paper, we presented the development of a predictive
model that enabled detection of suspected AE under-reporting. Our model scored an AUC of the ROC curve of 0.62,
0.79, and 0.92 when tested at different scenarios: 25%, 50%,
and 75% of AE under-reporting, respectively. The model
is now being used by Quality Program Leads at Roche/
Genentech on a limited number of ongoing studies. It will
be deployed in production in the course of 2019/2020 and
will be applied to all ongoing clinical studies. This is part
of a broader effort at Roche/Genentech Product Quality to
leverage advanced analytics to augment and complement traditional clinical QA approaches. With regards to the model
itself, there are plans to enhance it in the coming months.
The next version will assess alternative machine learning
models (as explained in Sect. 4.). It will also integrate additional clinical study data sets and other data sources, such
as‚Äîbut not limited to‚Äîsite/study geographical location.
Acknowledgements Content review was provided by Antoinette Chan
and Elaine (Min) Zou, who were employed by Roche/Genentech at the
time this research was completed.

Compliance with Ethical Standards
Funding Funding for development and testing of the anomaly detection
system was supplied by Roche/Genentech.
Conflict of Interest Timoth√© M√©nard, Yves Barmaz, Bj√∂rn Koneswarakantha, Rich Bowling, and Leszek Popko were employed by Roche/
Genentech at the time this research was completed.
Ethics Statement All human subject data used in this analysis were
used in a de-identified format.

1053

Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning
Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any
noncommercial use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate
if changes were made.

11.

12.
13.

References
1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
E26(R2) Guideline for Good Clinical Practices. 2016. https‚Äã://
www.ich.org/filea‚Äãdmin/Publi‚Äãc_Web_Site/ICH_Produ‚Äãcts/Guide‚Äã
lines‚Äã/Effic‚Äãacy/E6/E6_R2__Step_4_2016_1109.pdf. Accessed 10
Dec 2018.
2. Medicine and Healthcare products Regulatory Agency. GCP
inspection metrics report. 2018. https‚Äã://asset‚Äãs.publi‚Äãshing‚Äã.servi‚Äã
ce.gov.uk/gover‚Äãnment‚Äã/uploa‚Äãds/syste‚Äãm/uploa‚Äãds/attac‚Äãhment‚Äã_data/
file/706356‚Äã /GCP_INSPEC
‚Äã TIONS
‚Äã _METRIC
‚Äã S_2016-2017__final‚Äã
_11-05-18_.pdf. Accessed 10 Dec 2018.
3. Food and Drug Administration. 2018 inspection data set. https‚Äã://
www.fda.gov/downl‚Äãoads/ICECI‚Äã/Inspe‚Äãction‚Äãs/UCM62‚Äã8362.xlsx.
Accessed 10 Dec 2018.
4. Food and Drug Administration. Guidance for Industry: Investigator Responsibilities ‚Äî Protecting the Rights, Safety, and Welfare
of Study Subjects. 2009. https‚Äã://www.fda.gov/downl‚Äãoads/Drugs‚Äã/
Guida‚ÄãnceCo‚Äãmplia‚ÄãnceRe‚Äãgulat‚ÄãoryIn‚Äãforma‚Äãtion/Guida‚Äãnces/UCM18‚Äã
7772.pdf. Accessed 10 Dec 2018.
5. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety
results in published reports of randomized controlled trials. Arch
Intern Med. 2009;169(19):1756‚Äì61.
6. Food and Drug Administration. Warning letter to AB Science
6/16/15 https‚Äã://www.fda.gov/ICECI‚Äã/Enfor‚Äãcemen‚ÄãtActi‚Äãons/Warni‚Äã
ngLet‚Äãters/ucm45‚Äã3979.htm. Accessed 10 Dec 2018.
7. Sacks L, Shamsuddin H, Yasinskaya Y, Bouri K, Lanthier M,
Sherman R. Scientific and regulatory reasons for delay and denial
of fda approval of initial applications for new drugs, 2000‚Äì2012.
JAMA. 2014;311(4):378‚Äì84.
8. Yazici Y. Some concerns about adverse event reporting in randomized clinical trials. Bull NYU Hosp Jt Dis. 2008;66(2):143‚Äì5.
9. Li H, Hawlk S, Hanna K, Klein G, Petteway S. Developing and
implementing a comprehensive clinical QA audit program. Qual
Assur J. 2007;11:128‚Äì37.
10. Food and Drug Administration. Guidance for industry: oversight
of clinical investigations‚Äîa risk-based approach to monitoring.

14.
15.
16.
17.
18.

19.
20.
21.
22.
23.
24.
25.

2013. https‚Äã://www.fda.gov/downl‚Äãoads/Drugs‚Äã/Guida‚Äãnces/UCM26‚Äã
9919.pdf. Accessed 10 Dec 2018.
Hurley C, Sinnott C, Clarke M, Kearney P, Racine E, Eustace J,
et al. Perceived barriers and facilitators to risk based monitoring in academic-led clinical trials: a mixed methods study. Trials.
2017;18:423.
Chandola V, Banerjee A, Kumar V. Anomaly detection: a survey.
ACM Comput Surveys. 2009;41(3):1‚Äì58.
Ceh, E. Adverse event reporting: during the study. 2009. https‚Äã
://first‚Äãclini‚Äãcal.com/journ‚Äãal/2009/0908_Adver‚Äãse_Repor ‚Äãting.pdf.
Accessed 10 Dec 2018.
Chaboyer W, Thalib L, Foster M, Ball C, Richards B. Predictors of
adverse events in patients after discharge from the intensive care
unit. Am Assoc Crit Care Nurs. 2008;17(3):255‚Äì63.
Study Data Tabulation Model (SDTM), v 1.6. 2017. https‚Äã://www.
cdisc‚Äã.org/stand‚Äãards/found‚Äãation‚Äãal/sdtm. Accessed 10 Dec 2018.
World Health Organisation. Anatomical therapeutic chemical
(ATC) classification system. https‚Äã://www.whocc‚Äã.no/atc_ddd_
index‚Äã/. Accessed 10 Dec 2018.
Singh S, Dhasmana DC, Bisht M, Singh PK. Pattern of adverse
drug reactions to anticancer drugs: a quantitative and qualitative
analysis. Indian J Med Paediatr Oncol. 2017;38(2):140‚Äì5.
Handelma GS, Kok HK, Chandra RV, Razavi AH, Huang S,
Brooks M, et al. Peering into the black box of artificial intelligence: evaluation metrics of machine learning methods. AJR Am
J Roentgenol. 2018;17:1‚Äì6.
Nelder J, Wedderburn R. Generalized linear models. J R Stat Soc.
1972;135(3):370‚Äì84.
Friedman J. Greedy function approximation: a gradient boosting
machine. Ann Stat. 2001;29(5):1189‚Äì232.
Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: data mining, inference and prediction. New York:
Springer; 2009.
Apache Hadoop. https‚Äã://hadoo‚Äãp.apach‚Äãe.org. Accessed on 10 Dec
2018.
H2O Sparkling Water. https‚Äã://www.h2o.ai/produ‚Äãcts/h2o-spark‚Äã
ling-water‚Äã. Accessed on 10 Dec 2018.
Youden WJ. Index for rating diagnostic tests. Cancer.
1950;3(1):32‚Äì5.
Fujita S, Seto K, Ito S, Wu Y, Huang CC, Hasegawa T. The
characteristics of patient safety culture in Japan, Taiwan and the
United States. BMC Health Serv Res. 2013;14(13):20.

